203 related articles for article (PubMed ID: 18556715)
1. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
Kintscher U
Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
[No Abstract] [Full Text] [Related]
2. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Di Marzo V
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
[No Abstract] [Full Text] [Related]
3. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
[No Abstract] [Full Text] [Related]
4. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
[TBL] [Abstract][Full Text] [Related]
5. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
[No Abstract] [Full Text] [Related]
6. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
7. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
[No Abstract] [Full Text] [Related]
8. [Rimonabant. Risk of depression has not been finally clarified].
Kreutzkamp B
Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079
[No Abstract] [Full Text] [Related]
9. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
10. Rimonabant, obesity and diabetes.
Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
[TBL] [Abstract][Full Text] [Related]
11. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC
Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063
[No Abstract] [Full Text] [Related]
12. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
[TBL] [Abstract][Full Text] [Related]
13. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
[TBL] [Abstract][Full Text] [Related]
14. Rimonabant: obituary for a wonder drug.
Boekholdt SM; Peters RJ
Lancet; 2010 Aug; 376(9740):489-90. PubMed ID: 20709215
[No Abstract] [Full Text] [Related]
15. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects of rimonabant: clinical implications.
Després JP
Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
[TBL] [Abstract][Full Text] [Related]
17. [Rimonabant (Acomplia)].
Duh D; Vanddevijver A
J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
[No Abstract] [Full Text] [Related]
18. Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE).
Boesten JE; Kaper J; Stoffers HE; Kroon AA; van Schayck OC
Fam Pract; 2012 Oct; 29(5):521-7. PubMed ID: 22389428
[TBL] [Abstract][Full Text] [Related]
19. [Prescription of rimonabant in the early stage of pregnancy?].
Picksak G; Stichtenoth DO
Med Monatsschr Pharm; 2008 Mar; 31(3):107-8. PubMed ID: 18429532
[TBL] [Abstract][Full Text] [Related]
20. [Sleep disorders associated with treatment with rimonabant].
Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
[No Abstract] [Full Text] [Related]
[Next] [New Search]